BiomX Inc (NYSEARCA:PHGE) Surges 142% After Stunning Q2 2025 Earnings Beat and Promising BX211 Phase 2 Results

BiomX Inc (NYSEARCA:PHGE) reported its second-quarter 2025 financial results, delivering a significant earnings surprise that has fueled a sharp upward movement in its stock price. The clinical-stage microbiome company posted earnings per share (EPS) of $0.19, far exceeding analyst expectations of a loss of $0.3315 per share. Revenue for the quarter came in at $0.0, matching consensus estimates.

Key Financial Highlights vs. Estimates

• EPS Beat: The reported EPS of $0.19 represents a substantial positive deviation from the anticipated loss of $0.3315. This unexpected profitability appears to be the primary driver behind the stock's pre-market surge of approximately 142%.
• Revenue In Line: As expected, BiomX recorded no revenue, given its status as a pre-revenue biotech firm focused on clinical development.
• Market Reaction: The stock has shown strong momentum over the past month, rising over 40%, with accelerated gains following the earnings release. The pre-market spike suggests investor optimism around the company’s progress.

Clinical and Operational Updates

The earnings release highlighted promising Phase 2 results for BX211, BiomX’s phage therapy targeting diabetic foot osteomyelitis (DFO). Key takeaways include:

• Efficacy: The treatment demonstrated a >40% reduction in wound size compared to placebo, a clinically meaningful outcome that could support advancement into a registrational study.
• Regulatory Pathway: Management indicated that planning is underway for a potential pivotal trial, signaling confidence in the program’s viability.

While the press release did not provide explicit financial guidance for upcoming quarters, the progress in BX211’s development likely contributed to the bullish sentiment. Analysts currently expect continued losses for Q3 2025 (EPS estimate: -$0.418) and full-year 2025 (EPS estimate: -$1.5606), but BiomX’s ability to outperform expectations this quarter may lead to revisions.

Broader Market Sentiment

The stock’s recent performance—up ~29% over the past week and ~36% over two weeks—reflects growing investor interest in BiomX’s pipeline. The absence of revenue remains a consideration, but the strong clinical data and earnings beat suggest that near-term catalysts, rather than commercialization, are driving valuation.

For a deeper dive into BiomX’s earnings and analyst estimates, visit the earnings estimates page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research or consult a financial advisor before making investment decisions.